{"transactions":[{"id":4616256,"issuer":{"id":4289,"kind":"organization","name":"AtaiBeckley Inc.","symbol":"ATAI"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true}}],"security":"Stock Option","published_at":"2026-09-11T21:44:23.000Z","date":"2026-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":121968,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":4.5,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":121968},"source":{"system":"sec-edgar","filing":"0001140361-26-036384","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126036384/form4.xml","form_type":"4"}},{"id":4616255,"issuer":{"id":4289,"kind":"organization","name":"AtaiBeckley Inc.","symbol":"ATAI"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true}}],"security":"Stock Option","published_at":"2026-09-11T21:44:23.000Z","date":"2026-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":103000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":2.25,"expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":103000},"source":{"system":"sec-edgar","filing":"0001140361-26-036384","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126036384/form4.xml","form_type":"4"}},{"id":4616254,"issuer":{"id":4289,"kind":"organization","name":"AtaiBeckley Inc.","symbol":"ATAI"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true}}],"security":"Stock Option","published_at":"2026-09-11T21:44:23.000Z","date":"2026-09-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":206000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the \"Company\"), Eli Lilly and Company, an Indiana corporation (\"Parent\"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent (\"Merger Sub\"), on September 11, 2026, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares of the Company's common stock subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one contingent value right per share (each, a \"CVR\" and collectively, the \"CVRs\"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding, for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":1.34,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":206000},"source":{"system":"sec-edgar","filing":"0001140361-26-036384","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126036384/form4.xml","form_type":"4"}},{"id":734191,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2026-06-18T00:30:07.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":1980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."}],"balance_after":1980,"derivative":{"underlying":"Common Stock","underlying_shares":1980},"source":{"system":"sec-edgar","filing":"0001379344-26-000005","document":"form4-06172026_080603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000137934426000005/form4-06172026_080603.xml","form_type":"4"}},{"id":734190,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-18T00:30:07.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":3772,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":3772,"derivative":{"exercise_price":101,"expiration_date":"2036-06-14","underlying":"Common Stock","underlying_shares":3772},"source":{"system":"sec-edgar","filing":"0001379344-26-000005","document":"form4-06172026_080603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000137934426000005/form4-06172026_080603.xml","form_type":"4"}},{"id":746600,"issuer":{"id":4289,"kind":"organization","name":"AtaiBeckley Inc.","symbol":"ATAI"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true}}],"security":"Stock Option","published_at":"2026-06-09T00:00:38.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":121968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to continued service on AtaiBeckley Inc.'s board of directors through the applicable vesting date."}],"balance_after":121968,"derivative":{"exercise_price":4.5,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":121968},"source":{"system":"sec-edgar","filing":"0001140361-26-024525","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2081043/000114036126024525/form4.xml","form_type":"4"}},{"id":754906,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-02T23:50:05.000Z","date":"2026-05-29","kind":"exercise","planned":false,"acquired":false,"shares":3977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests on May 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests on May 29, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3977},"source":{"system":"sec-edgar","filing":"0001379344-26-000003","document":"form4-06022026_070601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000137934426000003/form4-06022026_070601.xml","form_type":"4"}},{"id":754905,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T23:50:05.000Z","date":"2026-05-29","kind":"exercise","planned":false,"acquired":true,"shares":3977,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer)."}],"balance_after":10727,"source":{"system":"sec-edgar","filing":"0001379344-26-000003","document":"form4-06022026_070601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000137934426000003/form4-06022026_070601.xml","form_type":"4"}},{"id":974177,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":110420,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":10.14,"underlying":"Common Stock","underlying_shares":110420},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974176,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":67502,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":10.14,"underlying":"Common Stock","underlying_shares":67502},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974175,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":58497,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":10.14,"underlying":"Common Stock","underlying_shares":58497},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974174,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":10.14,"underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974173,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":10.14,"underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974172,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45499,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":10.14,"underlying":"Common Stock","underlying_shares":45499},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974171,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":68000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":10.14,"underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974170,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":120000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":10.14,"underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974169,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":4.2,"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974168,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.15,"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974167,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":93000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an \"Out-of-the-Money Option\"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.5,"underlying":"Common Stock","underlying_shares":93000},"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974166,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Common Stock - Performance Stock Units","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"other","planned":false,"acquired":false,"shares":522666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation, (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent.  After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit granted under a Company Equity Plan that was subject solely to performance-based vesting (\"Company PSU\") that was outstanding and unvested immediately prior to the Effective Time, was cancelled and in exchange for such cancellation, the holder of such cancelled Company PSU received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (x) the total number of Shares subject to such Company PSU immediately prior to the Effective Time, multiplied by (y) the Cash Consideration and (ii) one CVR for each share of Company Common Stock subject to such Company PSU immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation, (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent.  After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit granted under a Company Equity Plan that was subject solely to performance-based vesting (\"Company PSU\") that was outstanding and unvested immediately prior to the Effective Time, was cancelled and in exchange for such cancellation, the holder of such cancelled Company PSU received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (x) the total number of Shares subject to such Company PSU immediately prior to the Effective Time, multiplied by (y) the Cash Consideration and (ii) one CVR for each share of Company Common Stock subject to such Company PSU immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974165,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Common Stock - Performance Stock Units","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On September 12, 2025, the Compensation Committee of the Issuer Board approved the grant of performance stock units, effective as of the completion of two trading days following the public announcement of by the Issuer of the first to occur of either a change of control (as defined in the Issuer's 2024 Equity Incentive Award Plan) or a significant out-licensing transaction certified by the Compensation Committee. The closing of the Merger was a qualifying change of control, pursuant to which 100% of the total number of awards vested on the closing of such change of control."}],"balance_after":522666,"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974164,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Common Stock - Restricted Stock Units","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"other","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation, (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent.  After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit granted under a Company Equity Plan that was subject solely to time-based vesting (\"Company RSU\") that was outstanding and unvested immediately prior to the Effective Time was cancelled and in exchange for such cancellation, the holder of such cancelled Company RSU received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time, multiplied by (y) the Cash Consideration and (ii) one CVR for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time (without regard to vesting)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation, (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent.  After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit granted under a Company Equity Plan that was subject solely to time-based vesting (\"Company RSU\") that was outstanding and unvested immediately prior to the Effective Time was cancelled and in exchange for such cancellation, the holder of such cancelled Company RSU received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time, multiplied by (y) the Cash Consideration and (ii) one CVR for each share of Company Common Stock subject to such Company RSU immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974163,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"other","planned":false,"acquired":false,"shares":351513,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation, (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent.  After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the \"Merger Agreement\"), by and among the Issuer, Eli Lilly and Company (\"Parent\") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation, (\"Purchaser\"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the \"Cash Consideration\"); plus (ii) one non-tradable contingent value right (each, a \"CVR\"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the \"CVR Agreement\") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent.  After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the \"Merger\"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the \"Effective Time\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":974162,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-12-10T18:52:31.000Z","date":"2025-12-09","kind":"exercise","planned":false,"acquired":true,"shares":150000,"price":4.2,"value":630000.0,"ownership":{"direct":true},"balance_after":351513,"source":{"system":"sec-edgar","filing":"0001379344-25-000006","document":"form4-12102025_061224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000006/form4-12102025_061224.xml","form_type":"4"}},{"id":977368,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-12-09T02:45:06.000Z","date":"2025-12-08","kind":"purchase","planned":false,"acquired":true,"shares":117614,"price":4.31,"value":506916.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $4.25 to $4.32. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 600 shares purchased on May 21, 20125 and 600 shares purchased on November 20, 2025, pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated."}],"balance_after":201513,"source":{"system":"sec-edgar","filing":"0001379344-25-000004","document":"form4-12082025_091203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000004/form4-12082025_091203.xml","form_type":"4"}},{"id":977367,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-12-09T02:45:06.000Z","date":"2025-12-05","kind":"purchase","planned":false,"acquired":true,"shares":11085,"price":4.24,"value":47000.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $4.21 to $4.25. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 600 shares purchased on May 21, 20125 and 600 shares purchased on November 20, 2025, pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated."}],"balance_after":83899,"source":{"system":"sec-edgar","filing":"0001379344-25-000004","document":"form4-12082025_091203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000137934425000004/form4-12082025_091203.xml","form_type":"4"}},{"id":1099994,"issuer":{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true}}],"security":"Stock Option","published_at":"2025-06-27T21:31:16.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":103000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026."}],"balance_after":103000,"derivative":{"exercise_price":2.25,"expiration_date":"2035-06-26","underlying":"Common Shares","underlying_shares":103000},"source":{"system":"sec-edgar","filing":"0001140361-25-024019","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000114036125024019/form4.xml","form_type":"4"}},{"id":1104736,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":110420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on February 12, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 12, 2024, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 12, 2028, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":110420,"derivative":{"exercise_price":10.14,"expiration_date":"2034-02-11","underlying":"Common Stock","underlying_shares":110420},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104735,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":110420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"kind","element":"transactionCoding","label":"F11","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on February 12, 2024."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 12, 2024, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 12, 2028, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":0,"derivative":{"exercise_price":19.9,"expiration_date":"2034-02-11","underlying":"Common Stock","underlying_shares":110420},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104734,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":67502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on September 14, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The options vest in equal monthly installments over three years from September 14, 2022, such that all of the shares subject to the option shall become vested and exercisable as of September 14, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":67502,"derivative":{"exercise_price":10.14,"expiration_date":"2032-09-13","underlying":"Common Stock","underlying_shares":67502},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104733,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":67502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"kind","element":"transactionCoding","label":"F9","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on September 14, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The options vest in equal monthly installments over three years from September 14, 2022, such that all of the shares subject to the option shall become vested and exercisable as of September 14, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2032-09-13","underlying":"Common Stock","underlying_shares":67502},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104732,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":58497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on September 14, 2022 and is fully vested."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on September 14, 2022 and is fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":58497,"derivative":{"exercise_price":10.14,"expiration_date":"2032-09-13","underlying":"Common Stock","underlying_shares":58497},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104731,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":58497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"kind","element":"transactionCoding","label":"F8","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on September 14, 2022 and is fully vested."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on September 14, 2022 and is fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":0,"derivative":{"exercise_price":10.9,"expiration_date":"2032-09-13","underlying":"Common Stock","underlying_shares":58497},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104730,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on March 8, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vest in equal monthly installments over two years from August 16, 2023, such that all of the shares subject to the option shall become vested and exercisable as of  August 16, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":31500,"derivative":{"exercise_price":10.14,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104729,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"kind","element":"transactionCoding","label":"F5","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on March 8, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vest in equal monthly installments over two years from August 16, 2023, such that all of the shares subject to the option shall become vested and exercisable as of  August 16, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":0,"derivative":{"exercise_price":12.9,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104728,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on March 8, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 18, 2022, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 18, 2026, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":63000,"derivative":{"exercise_price":10.14,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104727,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"kind","element":"transactionCoding","label":"F5","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on March 8, 2022."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 18, 2022, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 18, 2026, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":0,"derivative":{"exercise_price":12.9,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104726,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":45499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on August 6, 2021 and is fully vested."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on August 6, 2021 and is fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":45499,"derivative":{"exercise_price":10.14,"expiration_date":"2031-08-05","underlying":"Common Stock","underlying_shares":45499},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104725,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on August 6, 2021 and is fully vested."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on August 6, 2021 and is fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":0,"derivative":{"exercise_price":24.8,"expiration_date":"2031-08-05","underlying":"Common Stock","underlying_shares":45499},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104724,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on February 16, 2021 and is fully vested."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on February 16, 2021 and is fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":68000,"derivative":{"exercise_price":10.14,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104723,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on February 16, 2021 and is fully vested."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on February 16, 2021 and is fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":0,"derivative":{"exercise_price":134.4,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104722,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and is fully vested."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and is fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":120000,"derivative":{"exercise_price":10.14,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1104721,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:27:24.000Z","date":"2025-06-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and is fully vested."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and is fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Effective March 21, 2024, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten."}],"balance_after":0,"derivative":{"exercise_price":237,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001415889-25-017862","document":"form4-06202025_080620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925017862/form4-06202025_080620.xml","form_type":"4"}},{"id":1127743,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-02T23:33:03.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":3977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting."}],"balance_after":3977,"derivative":{"underlying":"Common Stock","underlying_shares":3977},"source":{"system":"sec-edgar","filing":"0001415889-25-015300","document":"form4-06022025_110600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925015300/form4-06022025_110600.xml","form_type":"4"}},{"id":1127742,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T23:33:03.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":6268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting."}],"balance_after":6268,"derivative":{"exercise_price":44,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":6268},"source":{"system":"sec-edgar","filing":"0001415889-25-015300","document":"form4-06022025_110600.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588925015300/form4-06022025_110600.xml","form_type":"4"}},{"id":1144943,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-05-16T20:44:20.000Z","date":"2025-05-15","kind":"sale","planned":false,"acquired":false,"shares":9126,"price":2,"value":18252.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price reported is a weighted-average sale price. The shares were sold at prices ranging from $1.985 to $2.01. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":87488,"source":{"system":"sec-edgar","filing":"0001415889-25-013442","document":"form4-05162025_080516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925013442/form4-05162025_080516.xml","form_type":"4"}},{"id":1240292,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T21:05:11.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent (25%) of the total number shares subject to the Option shall vest and become exercisable one year after the Vesting Commencement Date, and one-forty-eighth (1/48th) of the total number of shares subject to the Option shall vest and become exercisable each month thereafter, so that all of the shares subject to the Option are vested and exercisable on the fourth (4th) anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each vesting date."}],"balance_after":150000,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001415889-25-005833","document":"form4-02272025_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925005833/form4-02272025_040201.xml","form_type":"4"}},{"id":1240291,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Common Stock","published_at":"2025-02-27T21:05:11.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock issuable upon settlement of a restricted stock unit (\"RSU\") grant that will vest as to one-third (1/3rd) of the total number of shares subject to this award on each anniversary of March 1, 2025 (the \"Vesting Commencement Date\"), so that all of the shares subject to the RSUs are vested on the third (3rd) annual anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 600 shares purchased on May 20, 2023, 600 shares purchased on November 20, 2023, 600 shares purchased on May 20, 2024 and 600 shares purchased on November 20, 2024, pursuant to the Issuer's 2014 Employee Stock Plan Purchase Plan, as amended and restated."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On March 21, 2024, the Common Stock of Issuer split 1-for-10, resulting in a proportionate reduction of Reporting Person's shares."}],"balance_after":96614,"source":{"system":"sec-edgar","filing":"0001415889-25-005833","document":"form4-02272025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588925005833/form4-02272025_040201.xml","form_type":"4"}},{"id":1439448,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-06T20:08:27.000Z","date":"2024-08-02","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the total number of shares subject to the Option shall vest and become exercisable on the first anniversary of August 2, 2024 (the \"Vesting Commencement Date\"), and 1/36 of the total number of shares subject to the Option shall vest and become exercisable each month thereafter, such that all of the shares shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer as of each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":7.15,"expiration_date":"2034-08-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-24-020822","document":"form4-08062024_080821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588924020822/form4-08062024_080821.xml","form_type":"4"}},{"id":1478637,"issuer":{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true}}],"security":"Stock Option","published_at":"2024-06-14T21:00:42.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":206000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest as to 1/3rd of the underlying shares on June 13, 2025 and as to the remaining underlying shares in twenty-four (24) substantially equal monthly installments thereafter, such that the option will become fully vested on June 13, 2027."}],"balance_after":206000,"derivative":{"exercise_price":1.34,"expiration_date":"2034-06-13","underlying":"Common Shares","underlying_shares":206000},"source":{"system":"sec-edgar","filing":"0001140361-24-030207","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000114036124030207/form4.xml","form_type":"4"}},{"id":1486944,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Stock Units","published_at":"2024-06-07T22:21:21.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":5703,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting.  Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting.  Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting.  Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer."}],"balance_after":5703,"derivative":{"underlying":"Common Stock","underlying_shares":5703},"source":{"system":"sec-edgar","filing":"0001415889-24-016065","document":"form4-06072024_100617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588924016065/form4-06072024_100617.xml","form_type":"4"}},{"id":1486943,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T22:21:21.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":8779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting."}],"balance_after":8779,"derivative":{"exercise_price":26.3,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":8779},"source":{"system":"sec-edgar","filing":"0001415889-24-016065","document":"form4-06072024_100617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000141588924016065/form4-06072024_100617.xml","form_type":"4"}},{"id":1580524,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-12T23:05:19.000Z","date":"2023-10-03","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the meeting of the performance condition of performance stock options previously granted to the Reporting Person, pursuant to which 1/24 of the total number of shares subject to the option vest and become exercisable each month following the date upon which the first cohort of patients in the LUNA trial were fully dosed (the \"Vesting Commencement Date\"), such that all of the shares shall be vested and exercisable as of the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. On October 3, 2023, the Issuer's Compensation Committee certified that the Vesting Commencement Date occurred on August 16, 2023."}],"balance_after":315000,"derivative":{"exercise_price":1.29,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001415889-24-007713","document":"form4-03122024_110350.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588924007713/form4-03122024_110350.xml","form_type":"4"}},{"id":1642740,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, PRESIDENT AND DIRECTOR"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T21:31:04.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":1104200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total number of shares subject to the option shall vest and become exercisable on the first anniversary of February 12, 2024 (the \"Vesting Commencement Date\"), and one-forty-eighth (1/48th) of the total number of shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable on the fourth (4th) anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":1104200,"derivative":{"exercise_price":1.99,"expiration_date":"2034-02-11","underlying":"Common Stock","underlying_shares":1104200},"source":{"system":"sec-edgar","filing":"0001415889-24-003746","document":"form4-02142024_090227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000141588924003746/form4-02142024_090227.xml","form_type":"4"}},{"id":1844651,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:31.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.08,"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-23-016488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016488/doc4.xml","form_type":"4"}},{"id":1844650,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:31.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.49,"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-23-016488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016488/doc4.xml","form_type":"4"}},{"id":1844649,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:31.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.3,"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-23-016488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016488/doc4.xml","form_type":"4"}},{"id":1844648,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:31.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":126000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":1,"underlying":"Common Stock","underlying_shares":126000},"source":{"system":"sec-edgar","filing":"0000899243-23-016488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016488/doc4.xml","form_type":"4"}},{"id":1844647,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:31.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":120000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":0.8411,"underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000899243-23-016488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016488/doc4.xml","form_type":"4"}},{"id":1844646,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:31.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":4.61,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-23-016488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016488/doc4.xml","form_type":"4"}},{"id":1844645,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:05:31.000Z","date":"2023-06-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) (\"Parent\"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the \"Effective Time\"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.41,"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-23-016488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323016488/doc4.xml","form_type":"4"}},{"id":1855969,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-14T21:40:50.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2024 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":28.97,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-23-037124","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919123037124/doc4.xml","form_type":"4"}},{"id":1923264,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-07T18:17:00.000Z","date":"2023-04-05","kind":"grant","planned":false,"acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2024 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event."}],"balance_after":80000,"derivative":{"exercise_price":4.08,"expiration_date":"2033-04-05","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-23-010978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924323010978/doc4.xml","form_type":"4"}},{"id":1946182,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Common Stock","published_at":"2023-03-17T22:01:25.000Z","date":"2023-03-15","kind":"sale","acquired":false,"shares":41239,"price":0.7816,"value":32232.4024,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,000 shares purchased on November 18, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated."}],"balance_after":692141,"source":{"system":"sec-edgar","filing":"0001209191-23-019835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919123019835/doc4.xml","form_type":"4"}},{"id":1972200,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T22:21:33.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":930000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total number of shares subject to the option shall vest and become exercisable on the first anniversary of March 1, 2023 (the \"Vesting Commencement Date\"), and one-forty-eighth (1/48th) of the total number of shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable on the fourth (4th) anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":930000,"derivative":{"exercise_price":0.75,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":930000},"source":{"system":"sec-edgar","filing":"0001209191-23-015781","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919123015781/doc4.xml","form_type":"4"}},{"id":2153366,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Common Stock","published_at":"2022-09-21T23:57:28.000Z","date":"2022-09-19","kind":"sale","acquired":false,"shares":41082,"price":1.0696,"value":43941.3072,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price reported is a weighted-average sale price. The shares were sold at prices ranging from $1.069589 to $1.0708. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 6,000 shares purchased on May 20, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated."}],"balance_after":727380,"source":{"system":"sec-edgar","filing":"0001209191-22-050951","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919122050951/doc4.xml","form_type":"4"}},{"id":2157071,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Performance Based Stock Option (Right to Buy)","published_at":"2022-09-16T22:58:01.000Z","date":"2022-09-14","kind":"grant","acquired":true,"shares":584978,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the Performance Based Stock Option shall vest and become exercisable upon certification by the Compensation Committee of the Board of Directors of the Issuer that one full Nasdaq trading session has elapsed since the Issuer's public disclosure of final topline results from the LUNA Phase 2 clinical trial of ADVM-022 in wet age-related macular degeneration (the \"Performance Based Stock Option Vesting Date\"), provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) from September 14, 2022 through the Performance Based Stock Option Vesting Date."}],"balance_after":584978,"derivative":{"exercise_price":1.09,"expiration_date":"2032-09-13","underlying":"Common Stock","underlying_shares":584978},"source":{"system":"sec-edgar","filing":"0001209191-22-050399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919122050399/doc4.xml","form_type":"4"}},{"id":2157070,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-16T22:58:01.000Z","date":"2022-09-14","kind":"grant","acquired":true,"shares":675022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in equal monthly installments over three years, such that all of the shares subject to the option shall become vested and exercisable as of the third anniversary of September 14, 2022, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date."}],"balance_after":675022,"derivative":{"exercise_price":1.09,"expiration_date":"2032-09-13","underlying":"Common Stock","underlying_shares":675022},"source":{"system":"sec-edgar","filing":"0001209191-22-050399","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919122050399/doc4.xml","form_type":"4"}},{"id":2242491,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T21:59:28.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":23.51,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-22-034635","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919122034635/doc4.xml","form_type":"4"}},{"id":2291686,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Common Stock","published_at":"2022-04-22T21:00:51.000Z","date":"2022-04-20","kind":"purchase","acquired":true,"shares":25000,"price":1.112,"value":27800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.10 to $1.14. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":762462,"source":{"system":"sec-edgar","filing":"0001209191-22-025414","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919122025414/doc4.xml","form_type":"4"}},{"id":2326582,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-17T20:50:49.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":630000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 18, 2022 (the \"Vesting Commencement Date\"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":630000,"derivative":{"exercise_price":1.29,"expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":630000},"source":{"system":"sec-edgar","filing":"0001209191-22-019628","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919122019628/doc4.xml","form_type":"4"}},{"id":2338745,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-11T19:42:01.000Z","date":"2022-03-09","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2023 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event."}],"balance_after":80000,"derivative":{"exercise_price":4.49,"expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-22-010772","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924322010772/doc4.xml","form_type":"4"}},{"id":2476863,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Common Stock","published_at":"2021-12-10T22:26:36.000Z","date":"2021-12-09","kind":"purchase","acquired":true,"shares":14323,"price":1.85,"value":26497.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.845 to $1.85. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":737462,"source":{"system":"sec-edgar","filing":"0001209191-21-069099","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919121069099/doc4.xml","form_type":"4"}},{"id":2476862,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Common Stock","published_at":"2021-12-10T22:26:36.000Z","date":"2021-12-08","kind":"purchase","acquired":true,"shares":10677,"price":1.79,"value":19111.83,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $1.75 to $1.80. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,000 shares purchased on May 20, 2021 inadvertently not reflected as held on the Reporting Person's prior Form 4 and 3,170 shares purchased on November 22, 2021, in each case pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated."}],"balance_after":723139,"source":{"system":"sec-edgar","filing":"0001209191-21-069099","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919121069099/doc4.xml","form_type":"4"}},{"id":2608202,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-11T01:23:55.000Z","date":"2021-08-06","kind":"grant","acquired":true,"shares":455000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest in equal monthly installments over three years, such that all of the shares subject to the option shall become vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":455000,"derivative":{"exercise_price":2.48,"expiration_date":"2031-08-05","underlying":"Common Stock","underlying_shares":455000},"source":{"system":"sec-edgar","filing":"0001209191-21-050747","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919121050747/doc4.xml","form_type":"4"}},{"id":2608201,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, President and Director"}}],"security":"Common Stock","published_at":"2021-08-11T01:23:55.000Z","date":"2021-08-06","kind":"grant","acquired":true,"shares":680000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the grants of performance stock units, pursuant to which: (a) 1/3 of the shares will vest upon dosing of the first subject in a Phase 2 clinical trial of ADVM-022 in wet age-related macular degeneration; (b) 1/3 of the shares will vest upon dosing of the first subject in a potentially registrational clinical trial of ADVM-022 or another product candidate owned or being developed by Adverum in wet age-related macular degeneration or another indication determined by the Compensation Committee to represent a significant unmet medical need; and (c) 1/3 of the shares will vest upon consummation of a strategic corporate transaction, not constituting a change in control, that is determined by the Compensation Committee to be transformative for Adverum, in each case contingent upon certification by the Compensation Committee of the achievement of such milestone and subject to the Reporting Person's continued service with the Issuer on each such vesting date. See Footnote 2."},{"field":"shares","element":"transactionShares","label":"F2","text":"Non-exclusive examples of a strategic corporate transaction are (i) a collaboration with another company for the development and commercialization of a major asset, (ii) a substantial royalty-based or other structured financing, and (iii) the acquisition or in-license of a significant asset for development and commercialization."}],"balance_after":706292,"source":{"system":"sec-edgar","filing":"0001209191-21-050747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919121050747/doc4.xml","form_type":"4"}},{"id":2677906,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-08T20:33:49.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2022 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":16.88,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-038921","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919121038921/doc4.xml","form_type":"4"}},{"id":2772918,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common Stock","published_at":"2021-03-24T23:47:46.000Z","date":"2021-03-24","kind":"purchase","acquired":true,"shares":10000,"price":9.878,"value":98780.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $9.71 to $9.98. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":26292,"source":{"system":"sec-edgar","filing":"0001209191-21-022934","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919121022934/doc4.xml","form_type":"4"}},{"id":2793076,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-12T18:46:46.000Z","date":"2021-03-10","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was granted on March 10, 2021 and vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2022 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. The stock option is subject to stockholder approval of an increase in the share reserve under the Company's 2017 Equity Incentive Plan, which approval must occur within one year from the grant date."}],"balance_after":80000,"derivative":{"exercise_price":3.3,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-21-011369","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924321011369/doc4.xml","form_type":"4"}},{"id":2849143,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-19T02:03:02.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":680000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 16, 2021 (the \"Vesting Commencement Date\"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":680000,"derivative":{"exercise_price":13.44,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":680000},"source":{"system":"sec-edgar","filing":"0001209191-21-012210","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919121012210/doc4.xml","form_type":"4"}},{"id":2903996,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common Stock","published_at":"2021-01-20T01:32:40.000Z","date":"2021-01-15","kind":"purchase","acquired":true,"shares":8600,"price":11.5338,"value":99190.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $11.44 to $11.60. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price."}],"balance_after":16292,"source":{"system":"sec-edgar","filing":"0001209191-21-004142","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919121004142/doc4.xml","form_type":"4"}},{"id":3051997,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common Stock","published_at":"2020-08-19T22:45:58.000Z","date":"2020-08-17","kind":"purchase","acquired":true,"shares":7692,"price":13,"value":99996.0,"ownership":{"direct":true},"balance_after":7692,"source":{"system":"sec-edgar","filing":"0001209191-20-047622","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919120047622/doc4.xml","form_type":"4"}},{"id":3106530,"issuer":{"id":71889,"kind":"organization","name":"Adverum Biotechnologies, Inc.","symbol":"ADVM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-17T21:12:47.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":1200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of June 15, 2020 (the \"Vesting Commencement Date\"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to 24 months of accelerated vesting and a 24-month post-termination exercise period in certain events, and subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":1200000,"derivative":{"exercise_price":23.7,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0001209191-20-037335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1379344/000120919120037335/doc4.xml","form_type":"4"}},{"id":3110713,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-15T20:17:22.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2021 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":16.71,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-20-036587","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919120036587/doc4.xml","form_type":"4"}},{"id":3212036,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2020-03-13T19:35:59.000Z","date":"2020-03-11","kind":"grant","acquired":true,"shares":126000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was granted on March 11, 2020 and vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2021 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. The stock option is subject to stockholder approval of an increase in the share reserve under the 2017 Equity Incentive Plan of the Company, which approval must occur within one year from the grant date."}],"balance_after":126000,"derivative":{"exercise_price":1,"expiration_date":"2030-03-11","underlying":"Common stock","underlying_shares":126000},"source":{"system":"sec-edgar","filing":"0000891293-20-000015","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129320000015/primary_doc.xml","form_type":"4"}},{"id":3411117,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-18T21:23:33.000Z","date":"2019-09-17","kind":"purchase","acquired":true,"shares":1648,"price":9.366,"value":15435.168,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average purchase price for the transaction reported was $9.36, and the range of prices were between $9.29 and $9.46. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":6750,"source":{"system":"sec-edgar","filing":"0001209191-19-050105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919119050105/doc4.xml","form_type":"4"}},{"id":3411116,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-18T21:23:33.000Z","date":"2019-09-16","kind":"purchase","acquired":true,"shares":452,"price":9.47,"value":4280.44,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $9.4698, and the range of prices were between $9.43 and $9.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":5102,"source":{"system":"sec-edgar","filing":"0001209191-19-050105","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919119050105/doc4.xml","form_type":"4"}},{"id":3418609,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-10T23:10:44.000Z","date":"2019-09-10","kind":"purchase","acquired":true,"shares":960,"price":10.2932,"value":9881.472,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average purchase price for the transaction reported was $10.2932, and the range of prices were between $9.91 and $10.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":4650,"source":{"system":"sec-edgar","filing":"0001209191-19-049089","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919119049089/doc4.xml","form_type":"4"}},{"id":3418608,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-10T23:10:44.000Z","date":"2019-09-09","kind":"purchase","acquired":true,"shares":300,"price":11.3,"value":3390.0,"ownership":{"direct":true},"balance_after":3690,"source":{"system":"sec-edgar","filing":"0001209191-19-049089","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919119049089/doc4.xml","form_type":"4"}},{"id":3418607,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-10T23:10:44.000Z","date":"2019-09-09","kind":"purchase","acquired":true,"shares":1670,"price":10.54,"value":17601.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average purchase price for the transaction reported was $10.54, and the range of prices were between $10.13 and $11.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":3390,"source":{"system":"sec-edgar","filing":"0001209191-19-049089","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919119049089/doc4.xml","form_type":"4"}},{"id":3418606,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-10T23:10:44.000Z","date":"2019-09-06","kind":"purchase","acquired":true,"shares":1720,"price":10.7147,"value":18429.284,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction reported was $10.7147, and the range of prices were between $10.50 and $10.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."}],"balance_after":1720,"source":{"system":"sec-edgar","filing":"0001209191-19-049089","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919119049089/doc4.xml","form_type":"4"}},{"id":3519401,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-05-20T18:46:50.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2020 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event."}],"balance_after":120000,"derivative":{"exercise_price":0.8411,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000891293-19-000046","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129319000046/primary_doc.xml","form_type":"4"}},{"id":3929287,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-05-17T19:17:57.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was granted on May 17, 2018 and vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2019 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event."}],"balance_after":60000,"derivative":{"exercise_price":4.61,"expiration_date":"2028-05-17","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000891293-18-000064","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089129318000064/primary_doc.xml","form_type":"4"}},{"id":4252183,"issuer":{"id":111865,"kind":"organization","name":"CTI BIOPHARMA CORP","symbol":"CTIC"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-25T17:12:55.000Z","date":"2017-07-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest on the first to occur of (1) July 21, 2018, (2) immediately prior to the first annual meeting of the Company's shareholders that occurs in 2018 and at which one or more members of the Board are to be elected, or (3) immediately prior to the occurrence of a Change in Control (as such term is defined in the 2017 Equity Incentive Plan), subject to Dr. Fischer's continued service through such date or event."}],"balance_after":50000,"derivative":{"exercise_price":3.41,"expiration_date":"2027-07-21","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-17-018917","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/891293/000089924317018917/doc4.xml","form_type":"4"}},{"id":4567439,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:21:33.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":258000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.91,"expiration_date":"2026-01-12","underlying":"Common Stock","underlying_shares":258000},"source":{"system":"sec-edgar","filing":"0001209191-16-148098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148098/doc4.xml","form_type":"4"}},{"id":4567438,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:21:33.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":105000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":14,"expiration_date":"2025-05-15","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001209191-16-148098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148098/doc4.xml","form_type":"4"}},{"id":4567437,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:21:33.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":503882,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":4.81,"expiration_date":"2024-04-27","underlying":"Common Stock","underlying_shares":503882},"source":{"system":"sec-edgar","filing":"0001209191-16-148098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148098/doc4.xml","form_type":"4"}},{"id":4567436,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:21:33.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":83324,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":4.81,"expiration_date":"2024-04-27","underlying":"Common Stock","underlying_shares":83324},"source":{"system":"sec-edgar","filing":"0001209191-16-148098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148098/doc4.xml","form_type":"4"}},{"id":4567435,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:21:33.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":16416,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.14,"expiration_date":"2021-05-31","underlying":"Common Stock","underlying_shares":16416},"source":{"system":"sec-edgar","filing":"0001209191-16-148098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148098/doc4.xml","form_type":"4"}},{"id":4567434,"issuer":{"id":181299,"kind":"organization","name":"Tobira Therapeutics, Inc.","symbol":"TBRA"},"owners":[{"id":37275,"kind":"person","name":"Fischer Laurent","position":1,"cik":"0001379344","reported_name":"Fischer Laurent","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-11-03T14:21:33.000Z","date":"2016-11-01","kind":"disposition_to_issuer","acquired":false,"shares":53616,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 19, 2016, by and among the Issuer, Allergan Holdco US, Inc. (\"Parent\") and Sapphire Acquisition Corp. (\"Purchaser\"), pursuant to which Purchaser was merged with and into Issuer (the \"Merger\"), each option to purchase shares (a \"Company Option\") of common stock, par value $0.001 per share, of Tobira Therapeutics, Inc. (the \"Shares\") that was then outstanding and unexercised, whether or not vested and which had a per-Share exercise price less than $28.35 per Share in cash (the \"Closing Amount\") (each, an \"In the Money Option\"), was cancelled and converted into the right to receive (i) a cash payment equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the effective time of the Merger (the \"Effective Time\")"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(continued from Footnote 1) and (ii) a contingent value right with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time. At the Effective Time, each Company Option other than an In the Money Option that was then outstanding and unexercised, whether or not vested (each, an \"Out of the Money Option\"), was cancelled and converted into the right to receive a cash payment, if any, from Parent with respect to each Share subject to such Out of the Money Option upon each date that a payment would be required to a holder of a contingent value right under the terms of the Contingent Value Rights Agreement (\"CVR Agreement\") on or prior to the fifth anniversary of the Effective Time (each such date, a \"Valuation Point\"),"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(continued from Footnote 1) equal to (i) the amount by which the sum of (A) the Closing Amount, (B) the amount per Share previously paid in respect of any earlier Valuation Points and (C) the amount per Share in cash to be paid at such Valuation Point under the CVR Agreement exceeds the exercise price payable per Share under such Out of the Money Option, less (ii) the amount of all payments previously received with respect to such Out of the Money Option. Notwithstanding the foregoing description, any Out of the Money Options with an exercise price payable per Share equal to or greater than $78.19 were cancelled at the Effective Time without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Shares subject to this option were fully vested immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":3.14,"expiration_date":"2020-11-30","underlying":"Common Stock","underlying_shares":53616},"source":{"system":"sec-edgar","filing":"0001209191-16-148098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311596/000120919116148098/doc4.xml","form_type":"4"}}],"next_cursor":"2016-11-03T14:21:33.000000Z,4567434"}